[go: up one dir, main page]

SG11201803958WA - Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences - Google Patents

Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences

Info

Publication number
SG11201803958WA
SG11201803958WA SG11201803958WA SG11201803958WA SG11201803958WA SG 11201803958W A SG11201803958W A SG 11201803958WA SG 11201803958W A SG11201803958W A SG 11201803958WA SG 11201803958W A SG11201803958W A SG 11201803958WA SG 11201803958W A SG11201803958W A SG 11201803958WA
Authority
SG
Singapore
Prior art keywords
international
nucleic acid
amino acid
repetitive
rich
Prior art date
Application number
SG11201803958WA
Inventor
Uli Binder
Stefan Achatz
Arne Skerra
Original Assignee
Xl Protein Gmbh
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xl Protein Gmbh, Univ Muenchen Tech filed Critical Xl Protein Gmbh
Publication of SG11201803958WA publication Critical patent/SG11201803958WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau (43) International Publication Date .... ....7:01 29 June 2017(29.06.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111111111111111111111111 2017/109087 Publication Al Number (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/62 (2006.01) C12N 15/11 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 38/00 (2006.01) C12N 15/64 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07K 14/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, ICH, KN, PCT/EP2016/082407 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 22 December 2016 (22.12.2016) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 15202093.9 22 December 2015 (22.12.2015) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicants: XL-PROTEIN GMBH [DE/DE]; Lise-Meit- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, ner-Str. 30, 85354 Freising (DE). TECHNISCHE UNI- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, VERSITAT MUNCHEN [DE/DE]; Arcisstras se 21, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 80333 Miinchen (DE). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: BINDER, Ulrich; Angerstr. 7, 85354 Freising SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (DE). ACHATZ, Stefan; Max-Lehner-Str. 24, 85354 Fre- ising (DE). SKERRA, Arne; Max-Lehner-Str. 19, 85354 Published: Freising (DE). 21(3)) — with international search report (Art (74) Agent: MEIER, Jurgen; Vossius & Partner, SiebertstraBe _ with sequence listing part of description (Rule 5.2(a)) 3, 81675 Miinchen (DE). 1-1 .4t N (54) Title: NUCLEIC ACIDS ENCODING REPETITIVE AMINO ACID SEQUENCES RICH IN PROLINE AND ALANINE GC RESIDUES THAT HAVE LOW REPETITIVE NUCLEOTIDE SEQUENCES 0 C(57) : The present invention relates to a nucleic acid molecule comprising a low repetitive nucleotide sequence encoding a • Il prolme/alanine-rich amino acid repeat sequence. The encoded polypeptide comprises a repetitive amino acid sequence that forms a *----- random coil. The nucleic acid molecule comprising said low repetitive nucleotide sequences can further comprise a nucleotide se - L -- quence encoding a biologically or pharmacologically active protein. Further, the present invention provides for selection means and ::::) methods to identify said nucleic acid molecule comprising said low repetitive nucleotide sequence. The present invention also relates ei to a method for preparing said nucleic acid molecules. Also provided herein are methods for preparing the encoded polypeptide or 0 drug conjugates with the encoded polypeptide using the herein provided nucleic acid molecules. The drug conjugate may comprise a biologically or pharmacologically active protein or a small molecule drug. Also provided herein are vectors and hosts comprising 5 such nucleic acid molecules.
SG11201803958WA 2015-12-22 2016-12-22 Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences SG11201803958WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15202093 2015-12-22
PCT/EP2016/082407 WO2017109087A1 (en) 2015-12-22 2016-12-22 Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences

Publications (1)

Publication Number Publication Date
SG11201803958WA true SG11201803958WA (en) 2018-07-30

Family

ID=55129435

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803958WA SG11201803958WA (en) 2015-12-22 2016-12-22 Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences

Country Status (19)

Country Link
US (1) US11401305B2 (en)
EP (2) EP3394266B1 (en)
JP (1) JP7065772B2 (en)
KR (1) KR102654180B1 (en)
CN (1) CN109153996B (en)
AU (1) AU2016378646B2 (en)
BR (1) BR112018012784A2 (en)
CA (1) CA3005115A1 (en)
DK (1) DK3394266T3 (en)
EA (1) EA201891127A1 (en)
ES (1) ES2877539T3 (en)
HU (1) HUE055267T2 (en)
IL (1) IL259352B (en)
LT (1) LT3394266T (en)
MX (1) MX2018007680A (en)
PL (1) PL3394266T3 (en)
SG (1) SG11201803958WA (en)
SI (1) SI3394266T1 (en)
WO (1) WO2017109087A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (en) 2014-01-08 2018-04-06 弗洛设计声能学公司 Sound electrophoretic apparatus with alliteration electrophoresis chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
CN111406071B (en) * 2017-11-16 2024-01-16 成都硕德药业有限公司 PAS-like VEGFR/PDGFR fusion proteins and their use in therapy
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy
AU2018385759B2 (en) 2017-12-14 2021-10-21 Flodesign Sonics, Inc. Acoustic transducer driver and controller
WO2019165345A1 (en) * 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating or preventing intestinal paracellular permeability
KR102209198B1 (en) * 2019-04-02 2021-02-02 주식회사 바이오앱 Recombinant Irisin gene optimized for plant expression and method for producing recombinant Irisin protein therefrom
CN110038120B (en) * 2019-04-02 2022-12-23 河南师范大学 Application of Leopard Frog Antitumor Enzyme Fusion Protein as a Drug for Treating Tumors
US12431219B2 (en) 2019-04-15 2025-09-30 Bruker Daltonics GmbH & Co. KG Methods for determining isomeric amino acid residues of proteins and peptides
WO2020227341A1 (en) 2019-05-06 2020-11-12 9 Meters Biopharma, Inc. Compositions and methods for treating sjogren's syndrome
BR112022007677A2 (en) 2019-10-25 2022-10-25 Jazz Pharmaceuticals Ireland Ltd RECOMBINANT L-ASPARAGINASE
IL303816A (en) 2020-12-22 2023-08-01 Xl Protein Gmbh Antibodies specific for structurally disordered sequences
CN117957237A (en) * 2021-05-14 2024-04-30 安特利亚生物科学公司 Modified type B natriuretic peptides
CN113340864B (en) * 2021-06-07 2023-04-07 郑州轻工业大学 Aptamer sensor for secondary amplification of INS signal based on MEF effect and preparation method and application thereof
CN114470170B (en) * 2022-02-22 2023-09-19 广州新济药业科技有限公司 A kind of semaglutide soluble microneedle composition and preparation method thereof
EP4577243A1 (en) 2022-08-26 2025-07-02 Ethris GmbH Stable lipid or lipidoid nanoparticle suspensions
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
KR20250121363A (en) * 2022-12-08 2025-08-12 인스메드 인코포레이티드 Our casein conjugate and method of use thereof
CN115851667A (en) * 2023-01-17 2023-03-28 陕西科技大学 A method for regulating the activity of recombinant nuclease
WO2025045767A1 (en) 2023-08-25 2025-03-06 Ethris Gmbh Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications
WO2025088193A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for efficient recombinant production of polypeptides
WO2025088192A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides
WO2025233381A1 (en) 2024-05-07 2025-11-13 Technische Universität München, in Vertretung des Freistaates Bayern Enzymes that eliminate pyrimidine and/or purine nucleosides for treating cancer
CN118979069B (en) * 2024-07-31 2025-03-18 广东省农业科学院植物保护研究所 Application of Chorion protein 36 in regulating the reproduction of female melon flies
CN119162200B (en) * 2024-11-04 2025-11-11 福建农林大学 Rice fresh seed spike germination resistant OsRDR gene, inDel marker and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20060252120A1 (en) 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
CA2649038A1 (en) 2006-05-30 2007-12-13 Dow Global Technolgies Inc. Codon optimization method
DK2173890T3 (en) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologically active proteins with increased stability in vivo and / or in vitro
CA2794614C (en) * 2010-05-21 2020-12-15 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
WO2015132004A1 (en) 2014-03-05 2015-09-11 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
EP3418383A1 (en) 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
KR102727396B1 (en) 2017-06-21 2024-11-08 재즈 파마슈티칼즈 아일랜드 리미티드 Modified L-asparaginase
CN110891612A (en) 2017-06-21 2020-03-17 Xl-蛋白有限责任公司 Conjugates of protein drugs and P/A peptides
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy

Also Published As

Publication number Publication date
KR20180088484A (en) 2018-08-03
MX2018007680A (en) 2018-11-14
EP3394266A1 (en) 2018-10-31
ES2877539T3 (en) 2021-11-17
DK3394266T3 (en) 2021-06-07
US11401305B2 (en) 2022-08-02
EP3394266B1 (en) 2021-04-14
AU2016378646A1 (en) 2018-06-14
IL259352B (en) 2022-02-01
JP2019508020A (en) 2019-03-28
SI3394266T1 (en) 2021-08-31
IL259352A (en) 2018-07-31
EA201891127A1 (en) 2019-01-31
HUE055267T2 (en) 2021-11-29
PL3394266T3 (en) 2021-12-13
AU2016378646B2 (en) 2023-03-09
US20190010192A1 (en) 2019-01-10
NZ742902A (en) 2023-12-22
JP7065772B2 (en) 2022-05-12
LT3394266T (en) 2021-08-25
KR102654180B1 (en) 2024-04-04
CA3005115A1 (en) 2017-06-29
EP3919623A1 (en) 2021-12-08
CN109153996A (en) 2019-01-04
BR112018012784A2 (en) 2019-02-05
WO2017109087A1 (en) 2017-06-29
CN109153996B (en) 2022-03-25

Similar Documents

Publication Publication Date Title
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201907846VA (en) Therapeutic rna
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201811432WA (en) Rna for cancer therapy
SG11201807912SA (en) Vaccine against rsv
SG11201907298WA (en) Methods and compositions for gene transfer across the vasculature
SG11201909918XA (en) Compositions and methods for improving sample identification in indexed nucleic acid libraries
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201803934YA (en) Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies